EcoDrugPlus

P2x Purinoceptor 3-Like

Ensembl ID : ENSXMAG00000009871
Gene Symbol: LOC102218124
3 Cross references
192 Possible Orthologues:

P2x Purinoceptor 4

Ensembl ID : ENSXMAG00000016836
Gene Symbol: LOC102233539
3 Cross references
191 Possible Orthologues:

P2y Purinoceptor 12-Like

Ensembl ID : ENSXMAG00000025279
Gene Symbol: LOC102237608
3 Cross references
180 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSXMAG00000004577
Gene Symbol: PIM3
3 Cross references
172 Possible Orthologues:

Rac-Gamma Serine/threonine-Protein Kinase

Ensembl ID : ENSXMAG00000013812
Gene Symbol: LOC102237954
3 Cross references
203 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSXMAG00000017691
Gene Symbol: RAF1
3 Cross references
207 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSXMAG00000002398
Gene Symbol: ROCK1
3 Cross references
213 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSXMAG00000009185
Gene Symbol: ROCK2
3 Cross references
225 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSXMAG00000017805
Gene Symbol: ROCK2
3 Cross references
225 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSXMAG00000000752
Gene Symbol: SEM1
1 Cross references
155 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSXMAG00000010238
Gene Symbol: SRC
4 Cross references
192 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSXMAG00000000566
Gene Symbol: LOC102222719
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).